vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and GAIA, INC (GAIA). Click either name above to swap in a different company.
GAIA, INC is the larger business by last-quarter revenue ($25.5M vs $16.1M, roughly 1.6× Journey Medical Corp). GAIA, INC runs the higher net margin — -0.3% vs -7.8%, a 7.5% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs 5.8%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs 9.4%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
Gaia, Inc. is a publicly traded (NASDAQ:GAIA) American media company founded in 1988 by Jirka Rysavy in Louisville, Colorado. It owns and operates Gaia TV, a subscription video on-demand service consisting of original and licensed alternative media documentaries, including those on wellness, spirituality and conspiracy theories.
DERM vs GAIA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $25.5M |
| Net Profit | $-1.2M | $-75.0K |
| Gross Margin | — | 87.6% |
| Operating Margin | -2.8% | -2.6% |
| Net Margin | -7.8% | -0.3% |
| Revenue YoY | 27.3% | 5.8% |
| Net Profit YoY | -182.0% | 91.7% |
| EPS (diluted) | $-0.04 | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $25.5M | ||
| Q3 25 | $17.0M | $25.0M | ||
| Q2 25 | $15.0M | $24.6M | ||
| Q1 25 | $13.1M | $23.8M | ||
| Q4 24 | $12.6M | $24.1M | ||
| Q3 24 | $14.6M | $22.0M | ||
| Q2 24 | $14.9M | $21.9M | ||
| Q1 24 | $13.0M | $21.3M |
| Q4 25 | $-1.2M | $-75.0K | ||
| Q3 25 | $-2.3M | $-1.2M | ||
| Q2 25 | $-3.8M | $-2.0M | ||
| Q1 25 | $-4.1M | $-1.2M | ||
| Q4 24 | $1.5M | $-907.0K | ||
| Q3 24 | $-2.4M | $-1.2M | ||
| Q2 24 | $-3.4M | $-2.2M | ||
| Q1 24 | $-10.4M | $-971.0K |
| Q4 25 | — | 87.6% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | — | 86.7% | ||
| Q1 25 | — | 87.7% | ||
| Q4 24 | 82.3% | 88.2% | ||
| Q3 24 | 63.9% | 86.1% | ||
| Q2 24 | 56.0% | 84.5% | ||
| Q1 24 | 47.7% | 85.3% |
| Q4 25 | -2.8% | -2.6% | ||
| Q3 25 | -9.0% | -5.0% | ||
| Q2 25 | -19.2% | -8.9% | ||
| Q1 25 | -25.3% | -4.3% | ||
| Q4 24 | 17.7% | -7.1% | ||
| Q3 24 | -19.8% | -5.3% | ||
| Q2 24 | -19.7% | -9.1% | ||
| Q1 24 | -77.4% | -4.0% |
| Q4 25 | -7.8% | -0.3% | ||
| Q3 25 | -13.6% | -4.6% | ||
| Q2 25 | -25.3% | -8.3% | ||
| Q1 25 | -31.0% | -5.1% | ||
| Q4 24 | 12.1% | -3.8% | ||
| Q3 24 | -16.3% | -5.4% | ||
| Q2 24 | -22.6% | -9.9% | ||
| Q1 24 | -80.1% | -4.6% |
| Q4 25 | $-0.04 | $-0.02 | ||
| Q3 25 | $-0.09 | $-0.05 | ||
| Q2 25 | $-0.16 | $-0.07 | ||
| Q1 25 | $-0.18 | $-0.04 | ||
| Q4 24 | $0.10 | $-0.03 | ||
| Q3 24 | $-0.12 | $-0.05 | ||
| Q2 24 | $-0.17 | $-0.09 | ||
| Q1 24 | $-0.53 | $-0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $13.5M |
| Total DebtLower is stronger | $25.3M | — |
| Stockholders' EquityBook value | $31.9M | $87.9M |
| Total Assets | $94.6M | $154.6M |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $13.5M | ||
| Q3 25 | $24.9M | $14.2M | ||
| Q2 25 | $20.3M | $13.9M | ||
| Q1 25 | $21.1M | $13.1M | ||
| Q4 24 | $20.3M | $5.9M | ||
| Q3 24 | $22.5M | $4.4M | ||
| Q2 24 | $23.9M | $5.5M | ||
| Q1 24 | $24.1M | $8.6M |
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $14.7M | — |
| Q4 25 | $31.9M | $87.9M | ||
| Q3 25 | $25.9M | $86.3M | ||
| Q2 25 | $19.2M | $85.7M | ||
| Q1 25 | $21.5M | $87.0M | ||
| Q4 24 | $20.1M | $80.7M | ||
| Q3 24 | $10.9M | $81.2M | ||
| Q2 24 | $11.3M | $82.1M | ||
| Q1 24 | $13.0M | $84.8M |
| Q4 25 | $94.6M | $154.6M | ||
| Q3 25 | $85.2M | $151.1M | ||
| Q2 25 | $81.2M | $147.0M | ||
| Q1 25 | $85.0M | $148.5M | ||
| Q4 24 | $80.2M | $141.2M | ||
| Q3 24 | $64.0M | $139.6M | ||
| Q2 24 | $65.2M | $142.1M | ||
| Q1 24 | $66.6M | $133.8M |
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $1.8M |
| Free Cash FlowOCF − Capex | — | $76.0K |
| FCF MarginFCF / Revenue | — | 0.3% |
| Capex IntensityCapex / Revenue | — | 6.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-377.0K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $1.8M | ||
| Q3 25 | $-2.4M | $326.0K | ||
| Q2 25 | $-942.0K | $2.3M | ||
| Q1 25 | $-2.8M | $1.3M | ||
| Q4 24 | $2.2M | $2.7M | ||
| Q3 24 | $-1.2M | $409.0K | ||
| Q2 24 | $-5.2M | $-2.1M | ||
| Q1 24 | $-5.0M | $5.9M |
| Q4 25 | — | $76.0K | ||
| Q3 25 | — | $-1.6M | ||
| Q2 25 | — | $880.0K | ||
| Q1 25 | — | $268.0K | ||
| Q4 24 | — | $1.6M | ||
| Q3 24 | — | $-952.0K | ||
| Q2 24 | — | $-3.5M | ||
| Q1 24 | — | $4.9M |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | -6.4% | ||
| Q2 25 | — | 3.6% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 6.5% | ||
| Q3 24 | — | -4.3% | ||
| Q2 24 | — | -16.1% | ||
| Q1 24 | — | 22.8% |
| Q4 25 | — | 6.6% | ||
| Q3 25 | — | 7.7% | ||
| Q2 25 | — | 5.7% | ||
| Q1 25 | — | 4.3% | ||
| Q4 24 | — | 4.6% | ||
| Q3 24 | — | 6.2% | ||
| Q2 24 | — | 6.6% | ||
| Q1 24 | — | 5.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
GAIA
| US | $16.7M | 65% |
| Non Us | $8.8M | 35% |
